Promising antibody drug takes on hard-to-treat bone marrow cancer
NCT ID NCT04517851
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether elotuzumab can help people with a specific type of myelofibrosis, a serious bone marrow disorder. The drug targets a protein on cancer cells to try to improve blood counts, shrink an enlarged spleen, and ease symptoms. The trial includes 15 adults with JAK2-mutated disease who have not responded well to other treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS TRANSFORMATION IN ESSENTIAL THROMBOCYTHEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Dual-Action pill tame bone marrow tumors?
- Can a new pill shrink the spleen in myelofibrosis?
- Can a daily pill shrink the spleen in myelofibrosis?
- Can a new daily pill shrink the spleen and ease myelofibrosis symptoms?
- Could a platelet-boosting drug shorten recovery after stem cell transplants?
- Can a modified interferon rein in early myelofibrosis?